Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 303

1.

Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.

Zanfi C, Lauro A, Cescon M, Dazzi A, Ercolani G, Grazi GL, Zanello M, Vivarelli M, Del Gaudio M, Ravaioli M, Cucchetti A, Vetrone G, Tuci F, Di Gioia P, Lazzarotto T, D'Errico A, Bagni A, Faenza S, Siniscalchi A, Pironi L, Pinna AD.

Transplant Proc. 2010 Jan-Feb;42(1):35-8. doi: 10.1016/j.transproceed.2009.12.019.

PMID:
20172276
2.

Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.

Lauro A, Amaduzzi A, Dazzi A, Ercolani G, Zanfi C, Golfieri L, Grazi GL, Vivarelli M, Cescon M, Varotti G, Del Gaudio M, Ravaioli M, Siniscalchi A, Faenza S, D'Errico A, Di Simone M, Pironi L, Pinna AD.

Dig Liver Dis. 2007 Mar;39(3):253-6. Epub 2007 Feb 1.

PMID:
17275428
3.

Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.

Garcia M, Weppler D, Mittal N, Nishida S, Kato T, Tzakis A, Ruiz P.

Transplant Proc. 2004 Mar;36(2):323-4.

PMID:
15050146
4.

Intestinal and multivisceral transplantation immunosuppression protocols--literature review.

Trevizol AP, David AI, Dias ER, Mantovani D, Pécora R, D'Albuquerque LA.

Transplant Proc. 2012 Oct;44(8):2445-8. doi: 10.1016/j.transproceed.2012.07.016. Review.

PMID:
23026616
5.

Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation.

Tzakis AG, Kato T, Nishida S, Levi DM, Madariaga JR, Nery JR, Mittal N, Regev A, Cantwell P, Gyamfi A, Weppler D, Miller J, Tryphonopoulos P, Ruiz P.

Transplantation. 2003 Apr 27;75(8):1227-31.

PMID:
12717207
6.

Evolutionary experience with immunosuppression in pediatric intestinal transplantation.

Bond GJ, Mazariegos GV, Sindhi R, Abu-Elmagd KM, Reyes J.

J Pediatr Surg. 2005 Jan;40(1):274-9; discussion 279-80.

PMID:
15868597
7.

Impact of induction therapy on bacterial infections and long-term outcome in adult intestinal and multivisceral transplantation: a comparison of two different induction protocols: daclizumab vs. alemtuzumab.

Kimura T, Lauro A, Cescon M, Zanfi C, Dazzi A, Ercolani G, Grazi GL, Vivarelli M, Ravaioli M, Del Gaudio M, Cucchetti A, Zanello M, LaBarba G, Pironi L, Lazzarotto T, Pinna AD.

Clin Transplant. 2009 Jun-Jul;23(3):420-5.

PMID:
19537304
8.

Twenty-five consecutive isolated intestinal transplants in adult patients: a five-yr clinical experience.

Lauro A, Zanfi C, Ercolani G, Dazzi A, Golfieri L, Amaduzzi A, Grazi GL, Vivarelli M, Cescon M, Varotti G, Del Gaudio M, Ravaioli M, Pironi L, Pinna AD.

Clin Transplant. 2007 Mar-Apr;21(2):177-85.

PMID:
17425742
9.

Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation.

Tzakis AG, Kato T, Nishida S, Levi DM, Tryphonopoulos P, Madariaga JR, De Faria W, Nery JR, Regev A, Vianna R, Miller J, Esquenazi V, Weppler D, Ruiz P.

Transplantation. 2003 May 15;75(9):1512-7.

PMID:
12792506
10.

Twenty-seven consecutive intestinal and multivisceral transplants in adult patients: a 4-year clinical experience.

Lauro A, Di Benedetto F, Masetti M, Cautero N, Ercolani G, Vivarelli M, De Ruvo N, Cescon M, Varotti G, Dazzi A, Siniscalchi A, Begliomini B, Pironi L, Di Simone M, D'Errico A, Ramacciato G, Grazi G, Pinna AD.

Transplant Proc. 2005 Jul-Aug;37(6):2679-81.

PMID:
16182782
11.

Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China.

Yuan-Xin L, Ning L, You-Sheng L, Xiao-Dong N, Ming L, Jian W, Jie-Shou L.

Transplant Proc. 2010 Jan-Feb;42(1):29-34. doi: 10.1016/j.transproceed.2009.12.028.

PMID:
20172275
12.

Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.

Muñoz AS, Cabanayan-Casasola CB, Danguilan RA, Padua FB, Ona ET.

Transplant Proc. 2008 Sep;40(7):2230-3. doi: 10.1016/j.transproceed.2008.07.085.

PMID:
18790200
13.

Five-year outcomes with alemtuzumab induction after lung transplantation.

Shyu S, Dew MA, Pilewski JM, DeVito Dabbs AJ, Zaldonis DB, Studer SM, Crespo MM, Toyoda Y, Bermudez CA, McCurry KR.

J Heart Lung Transplant. 2011 Jul;30(7):743-54. doi: 10.1016/j.healun.2011.01.714. Epub 2011 Mar 21.

14.

Results of intestinal and multivisceral transplantation in adult patients: Italian experience.

Lauro A, Dazzi A, Ercolani G, Cescon M, D'Errico A, Di Simone M, Grazi GL, Vivarelli M, Varotti G, De Ruvo N, Masetti M, Cautero N, Di Benedetto F, Siniscalchi A, Begliomini B, Lazzarotto T, Faenza S, Pironi L, Pinna AD.

Transplant Proc. 2006 Jul-Aug;38(6):1696-8.

PMID:
16908252
15.

Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation.

Vianna RM, Mangus RS, Fridell JA, Weigman S, Kazimi M, Tector J.

Transplantation. 2008 May 15;85(9):1290-3. doi: 10.1097/TP.0b013e31816dd450.

PMID:
18475186
16.

Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.

Lü TM, Yang SL, Wu WZ, Tan JM.

Chin Med J (Engl). 2011 Mar;124(5):664-8.

PMID:
21518554
17.

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

Watson CJ, Bradley JA, Friend PJ, Firth J, Taylor CJ, Bradley JR, Smith KG, Thiru S, Jamieson NV, Hale G, Waldmann H, Calne R.

Am J Transplant. 2005 Jun;5(6):1347-53.

18.

Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.

Sampaio MS, Kadiyala A, Gill J, Bunnapradist S.

Transplantation. 2009 Oct 15;88(7):904-10. doi: 10.1097/TP.0b013e3181b724a5.

PMID:
19935462
19.

Alemtuzumab induction in deceased donor kidney transplantation.

Shin M, Song SH, Kim JM, Kwon CH, Joh JW, Lee SK, Kim SJ.

Transplant Proc. 2011 Jul-Aug;43(6):2365-78. doi: 10.1016/j.transproceed.2011.05.032.

PMID:
21839271
20.

Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.

Bumgardner GL, Ramos E, Lin A, Vincenti F; Daclizumab Triple Therapy and Double Therapy Groups.

Transplantation. 2001 Aug 27;72(4):642-7.

PMID:
11544424

Supplemental Content

Support Center